Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Austin Private Wealth LLC

Austin Private Wealth LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 786 shares of the medical research company’s stock after buying an additional 84 shares during the period. Austin Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $409,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at approximately $27,000. Missouri Trust & Investment Co acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Endeavor Private Wealth Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Finally, Decker Retirement Planning Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $43,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $598.40 on Friday. The business’s 50-day simple moving average is $539.66 and its 200-day simple moving average is $570.59. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The firm has a market cap of $228.89 billion, a price-to-earnings ratio of 37.52, a P/E/G ratio of 3.89 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total value of $5,581,200.00. Following the completion of the sale, the chief executive officer now owns 33,608 shares in the company, valued at approximately $18,757,296.96. This trade represents a 22.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 29,000 shares of company stock worth $15,859,540 in the last 90 days. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TMO. Evercore ISI lowered their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target for the company. Bernstein Bank upped their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. TD Cowen upped their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Finally, Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $655.64.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.